AustralieFrV1, PascalFrancis, Curation, bibRecord, 003401

Drug Treatment and Cost of Cardiovascular Disease in Australia

Identifieur interne : 003401 ( PascalFrancis/Curation ); précédent : 003400; suivant : 003402

Drug Treatment and Cost of Cardiovascular Disease in Australia

Auteurs : Zanfina Ademi [Australie] ; Danny Liew [Australie] ; Derek Chew [Australie] ; Greg Conner [Australie] ; Louise Shiel [Australie] ; Mark Nelson [Australie] ; Ash Soman [Australie] ; Gabriel Steg [France] ; Deepak L. Bhatt [États-Unis] ; Christopher Reid [Australie]

Source :

Cardiovascular therapeutics : (Print) [ 1755-5914 ] ; 2009.

RBID : Pascal:09-0362027

Descripteurs français

Pascal (Inist)
- Médicament, Traitement, Coût moyen, Economie santé, Pathologie de l'appareil circulatoire, Australie, Médecine.
Wicri :
- geographic : Australie.
- topic : Médicament, Médecine.

English descriptors

KwdEn :
- Australia, Average cost, Cardiovascular disease, Drug, Health economy, Medicine, Treatment.

Abstract

Australia's Pharmaceutical Benefits Scheme supports the use of effective drugs for the prevention and control of cardiovascular risk factors. However, there are little data available describing per person costs of medication in primary prevention and secondary prevention in the community. We aim to understand annual expenditure on cardiovascular medicines according to the level and extent of cardiovascular disease, using participants enrolled in the Reduction of Atherothrombosis for Continued Health (REACH) registry. 2873 participants were recruited into the REACH registry through 273 Australian general practices. Cardiovascular medicines review was undertaken at baseline. Average weighted costs of medications were estimated using government-reimbursed prices. Annual costs were stratified by disease extent and location. The annual mean cost of pharmaceuticals per person was AU$1307. The average reported medicine use per person across all states and participants groups varied significantly. Participants with cerebrovascular or peripheral arterial disease were prescribed less cardiovascular medication than those with coronary artery disease (CAD) (mean number of drugs 3.5 vs. 4.5, P < 0.0001) and (3.6 vs. 4.5, P < 0.0001), while those with risk factor alone had the same medication use as those with CAD (mean number 4.5). Medication use was lower in Western Australia in comparison to eastern States. Participants with existing cerebrovascular disease and peripheral vascular disease receive less preventive therapy than those with CAD or even risk factors alone. This observation is consistent across all mainland states. Given the evidence of the effectiveness and cost-effectiveness of treating all types of vascular diseases, the present study suggests that there is scope to improve the treatment of these high-risk participants in Australia.

A01	`01`	`1`		`@0 1755-5914`
A03		`1`		`@0 Cardiovasc. ther. : (Print)`
A05				`@2 27`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Drug Treatment and Cost of Cardiovascular Disease in Australia`
A11	`01`	`1`		`@1 ADEMI (Zanfina)`
A11	`02`	`1`		`@1 LIEW (Danny)`
A11	`03`	`1`		`@1 CHEW (Derek)`
A11	`04`	`1`		`@1 CONNER (Greg)`
A11	`05`	`1`		`@1 SHIEL (Louise)`
A11	`06`	`1`		`@1 NELSON (Mark)`
A11	`07`	`1`		`@1 SOMAN (Ash)`
A11	`08`	`1`		`@1 STEG (Gabriel)`
A11	`09`	`1`		`@1 BHATT (Deepak L.)`
A11	`10`	`1`		`@1 REID (Christopher)`
A14	`01`			`@1 Department of Epidemiology and Preventive Medicine, Centre for Cardiovascular Research and Education in Therapeutics, Monash University @2 Victoria @3 AUS @Z 1 aut. @Z 5 aut. @Z 10 aut.`
A14	`02`			`@1 Department of Medicine (St Vincent Hospital), University of Melbourne @2 Victoria @3 AUS @Z 2 aut.`
A14	`03`			`@1 Department of Cardiology, Flinders Medical Centre @2 South Australia @3 AUS @Z 3 aut.`
A14	`04`			`@1 Liverpool Hospital @2 New South Wales @3 AUS @Z 4 aut.`
A14	`05`			`@1 Menzies Research Institute, University of Tasmania @2 Tasmania @3 AUS @Z 6 aut.`
A14	`06`			`@1 Sanofi-Aventis @3 AUS @Z 7 aut.`
A14	`07`			`@1 INSERM U-698, Université Paris 7 and AP-HP @2 Paris @3 FRA @Z 8 aut.`
A14	`08`			`@1 VA Boston Healthcare System and Brigham and Women's Hospital @2 Boston, MA @3 USA @Z 9 aut.`
A20				`@1 164-172`
A21				`@1 2009`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 21845 @5 354000172550100030`
A44				`@0 0000 @1 © 2009 INIST-CNRS. All rights reserved.`
A45				`@0 45 ref.`
A47	`01`	`1`		`@0 09-0362027`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Cardiovascular therapeutics : (Print)`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Australia's Pharmaceutical Benefits Scheme supports the use of effective drugs for the prevention and control of cardiovascular risk factors. However, there are little data available describing per person costs of medication in primary prevention and secondary prevention in the community. We aim to understand annual expenditure on cardiovascular medicines according to the level and extent of cardiovascular disease, using participants enrolled in the Reduction of Atherothrombosis for Continued Health (REACH) registry. 2873 participants were recruited into the REACH registry through 273 Australian general practices. Cardiovascular medicines review was undertaken at baseline. Average weighted costs of medications were estimated using government-reimbursed prices. Annual costs were stratified by disease extent and location. The annual mean cost of pharmaceuticals per person was AU$1307. The average reported medicine use per person across all states and participants groups varied significantly. Participants with cerebrovascular or peripheral arterial disease were prescribed less cardiovascular medication than those with coronary artery disease (CAD) (mean number of drugs 3.5 vs. 4.5, P < 0.0001) and (3.6 vs. 4.5, P < 0.0001), while those with risk factor alone had the same medication use as those with CAD (mean number 4.5). Medication use was lower in Western Australia in comparison to eastern States. Participants with existing cerebrovascular disease and peripheral vascular disease receive less preventive therapy than those with CAD or even risk factors alone. This observation is consistent across all mainland states. Given the evidence of the effectiveness and cost-effectiveness of treating all types of vascular diseases, the present study suggests that there is scope to improve the treatment of these high-risk participants in Australia.
C02	`01`	`X`		`@0 002B02F`
C03	`01`	`X`	`FRE`	`@0 Médicament @5 01`
C03	`01`	`X`	`ENG`	`@0 Drug @5 01`
C03	`01`	`X`	`SPA`	`@0 Medicamento @5 01`
C03	`02`	`X`	`FRE`	`@0 Traitement @5 02`
C03	`02`	`X`	`ENG`	`@0 Treatment @5 02`
C03	`02`	`X`	`SPA`	`@0 Tratamiento @5 02`
C03	`03`	`X`	`FRE`	`@0 Coût moyen @5 03`
C03	`03`	`X`	`ENG`	`@0 Average cost @5 03`
C03	`03`	`X`	`SPA`	`@0 Coste medio @5 03`
C03	`04`	`X`	`FRE`	`@0 Economie santé @5 04`
C03	`04`	`X`	`ENG`	`@0 Health economy @5 04`
C03	`04`	`X`	`SPA`	`@0 Economía salud @5 04`
C03	`05`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 05`
C03	`05`	`X`	`ENG`	`@0 Cardiovascular disease @5 05`
C03	`05`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 05`
C03	`06`	`X`	`FRE`	`@0 Australie @2 NG @5 06`
C03	`06`	`X`	`ENG`	`@0 Australia @2 NG @5 06`
C03	`06`	`X`	`SPA`	`@0 Australia @2 NG @5 06`
C03	`07`	`X`	`FRE`	`@0 Médecine @5 07`
C03	`07`	`X`	`ENG`	`@0 Medicine @5 07`
C03	`07`	`X`	`SPA`	`@0 Medicina @5 07`
C07	`01`	`X`	`FRE`	`@0 Océanie @2 NG`
C07	`01`	`X`	`ENG`	`@0 Oceania @2 NG`
C07	`01`	`X`	`SPA`	`@0 Oceania @2 NG`
N21				`@1 264`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002C21

Links to Exploration step

Pascal:09-0362027

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Drug Treatment and Cost of Cardiovascular Disease in Australia</title>
<author><name sortKey="Ademi, Zanfina" sort="Ademi, Zanfina" uniqKey="Ademi Z" first="Zanfina" last="Ademi">Zanfina Ademi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Epidemiology and Preventive Medicine, Centre for Cardiovascular Research and Education in Therapeutics, Monash University</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Liew, Danny" sort="Liew, Danny" uniqKey="Liew D" first="Danny" last="Liew">Danny Liew</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine (St Vincent Hospital), University of Melbourne</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Chew, Derek" sort="Chew, Derek" uniqKey="Chew D" first="Derek" last="Chew">Derek Chew</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Cardiology, Flinders Medical Centre</s1>
<s2>South Australia</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Conner, Greg" sort="Conner, Greg" uniqKey="Conner G" first="Greg" last="Conner">Greg Conner</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Liverpool Hospital</s1>
<s2>New South Wales</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Shiel, Louise" sort="Shiel, Louise" uniqKey="Shiel L" first="Louise" last="Shiel">Louise Shiel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Epidemiology and Preventive Medicine, Centre for Cardiovascular Research and Education in Therapeutics, Monash University</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Nelson, Mark" sort="Nelson, Mark" uniqKey="Nelson M" first="Mark" last="Nelson">Mark Nelson</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Menzies Research Institute, University of Tasmania</s1>
<s2>Tasmania</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Soman, Ash" sort="Soman, Ash" uniqKey="Soman A" first="Ash" last="Soman">Ash Soman</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Sanofi-Aventis</s1>
<s3>AUS</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Steg, Gabriel" sort="Steg, Gabriel" uniqKey="Steg G" first="Gabriel" last="Steg">Gabriel Steg</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>INSERM U-698, Université Paris 7 and AP-HP</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L." last="Bhatt">Deepak L. Bhatt</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>VA Boston Healthcare System and Brigham and Women's Hospital</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Reid, Christopher" sort="Reid, Christopher" uniqKey="Reid C" first="Christopher" last="Reid">Christopher Reid</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Epidemiology and Preventive Medicine, Centre for Cardiovascular Research and Education in Therapeutics, Monash University</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0362027</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0362027 INIST</idno>
<idno type="RBID">Pascal:09-0362027</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002C21</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003401</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Drug Treatment and Cost of Cardiovascular Disease in Australia</title>
<author><name sortKey="Ademi, Zanfina" sort="Ademi, Zanfina" uniqKey="Ademi Z" first="Zanfina" last="Ademi">Zanfina Ademi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Epidemiology and Preventive Medicine, Centre for Cardiovascular Research and Education in Therapeutics, Monash University</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Liew, Danny" sort="Liew, Danny" uniqKey="Liew D" first="Danny" last="Liew">Danny Liew</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Medicine (St Vincent Hospital), University of Melbourne</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Chew, Derek" sort="Chew, Derek" uniqKey="Chew D" first="Derek" last="Chew">Derek Chew</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Cardiology, Flinders Medical Centre</s1>
<s2>South Australia</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Conner, Greg" sort="Conner, Greg" uniqKey="Conner G" first="Greg" last="Conner">Greg Conner</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Liverpool Hospital</s1>
<s2>New South Wales</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Shiel, Louise" sort="Shiel, Louise" uniqKey="Shiel L" first="Louise" last="Shiel">Louise Shiel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Epidemiology and Preventive Medicine, Centre for Cardiovascular Research and Education in Therapeutics, Monash University</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Nelson, Mark" sort="Nelson, Mark" uniqKey="Nelson M" first="Mark" last="Nelson">Mark Nelson</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Menzies Research Institute, University of Tasmania</s1>
<s2>Tasmania</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Soman, Ash" sort="Soman, Ash" uniqKey="Soman A" first="Ash" last="Soman">Ash Soman</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Sanofi-Aventis</s1>
<s3>AUS</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Steg, Gabriel" sort="Steg, Gabriel" uniqKey="Steg G" first="Gabriel" last="Steg">Gabriel Steg</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>INSERM U-698, Université Paris 7 and AP-HP</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Bhatt, Deepak L" sort="Bhatt, Deepak L" uniqKey="Bhatt D" first="Deepak L." last="Bhatt">Deepak L. Bhatt</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>VA Boston Healthcare System and Brigham and Women's Hospital</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Reid, Christopher" sort="Reid, Christopher" uniqKey="Reid C" first="Christopher" last="Reid">Christopher Reid</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Epidemiology and Preventive Medicine, Centre for Cardiovascular Research and Education in Therapeutics, Monash University</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Cardiovascular therapeutics : (Print)</title>
<title level="j" type="abbreviated">Cardiovasc. ther. : (Print)</title>
<idno type="ISSN">1755-5914</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Cardiovascular therapeutics : (Print)</title>
<title level="j" type="abbreviated">Cardiovasc. ther. : (Print)</title>
<idno type="ISSN">1755-5914</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Australia</term>
<term>Average cost</term>
<term>Cardiovascular disease</term>
<term>Drug</term>
<term>Health economy</term>
<term>Medicine</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Médicament</term>
<term>Traitement</term>
<term>Coût moyen</term>
<term>Economie santé</term>
<term>Pathologie de l'appareil circulatoire</term>
<term>Australie</term>
<term>Médecine</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Australie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médicament</term>
<term>Médecine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Australia's Pharmaceutical Benefits Scheme supports the use of effective drugs for the prevention and control of cardiovascular risk factors. However, there are little data available describing per person costs of medication in primary prevention and secondary prevention in the community. We aim to understand annual expenditure on cardiovascular medicines according to the level and extent of cardiovascular disease, using participants enrolled in the Reduction of Atherothrombosis for Continued Health (REACH) registry. 2873 participants were recruited into the REACH registry through 273 Australian general practices. Cardiovascular medicines review was undertaken at baseline. Average weighted costs of medications were estimated using government-reimbursed prices. Annual costs were stratified by disease extent and location. The annual mean cost of pharmaceuticals per person was AU$1307. The average reported medicine use per person across all states and participants groups varied significantly. Participants with cerebrovascular or peripheral arterial disease were prescribed less cardiovascular medication than those with coronary artery disease (CAD) (mean number of drugs 3.5 vs. 4.5, P < 0.0001) and (3.6 vs. 4.5, P < 0.0001), while those with risk factor alone had the same medication use as those with CAD (mean number 4.5). Medication use was lower in Western Australia in comparison to eastern States. Participants with existing cerebrovascular disease and peripheral vascular disease receive less preventive therapy than those with CAD or even risk factors alone. This observation is consistent across all mainland states. Given the evidence of the effectiveness and cost-effectiveness of treating all types of vascular diseases, the present study suggests that there is scope to improve the treatment of these high-risk participants in Australia.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1755-5914</s0>
</fA01>
<fA03 i2="1"><s0>Cardiovasc. ther. : (Print)</s0>
</fA03>
<fA05><s2>27</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Drug Treatment and Cost of Cardiovascular Disease in Australia</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ADEMI (Zanfina)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LIEW (Danny)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CHEW (Derek)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>CONNER (Greg)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SHIEL (Louise)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>NELSON (Mark)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>SOMAN (Ash)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>STEG (Gabriel)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>BHATT (Deepak L.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>REID (Christopher)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Epidemiology and Preventive Medicine, Centre for Cardiovascular Research and Education in Therapeutics, Monash University</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Medicine (St Vincent Hospital), University of Melbourne</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Cardiology, Flinders Medical Centre</s1>
<s2>South Australia</s2>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Liverpool Hospital</s1>
<s2>New South Wales</s2>
<s3>AUS</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Menzies Research Institute, University of Tasmania</s1>
<s2>Tasmania</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Sanofi-Aventis</s1>
<s3>AUS</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>INSERM U-698, Université Paris 7 and AP-HP</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>VA Boston Healthcare System and Brigham and Women's Hospital</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>164-172</s1>
</fA20>
<fA21><s1>2009</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>21845</s2>
<s5>354000172550100030</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2009 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>45 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>09-0362027</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Cardiovascular therapeutics : (Print)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Australia's Pharmaceutical Benefits Scheme supports the use of effective drugs for the prevention and control of cardiovascular risk factors. However, there are little data available describing per person costs of medication in primary prevention and secondary prevention in the community. We aim to understand annual expenditure on cardiovascular medicines according to the level and extent of cardiovascular disease, using participants enrolled in the Reduction of Atherothrombosis for Continued Health (REACH) registry. 2873 participants were recruited into the REACH registry through 273 Australian general practices. Cardiovascular medicines review was undertaken at baseline. Average weighted costs of medications were estimated using government-reimbursed prices. Annual costs were stratified by disease extent and location. The annual mean cost of pharmaceuticals per person was AU$1307. The average reported medicine use per person across all states and participants groups varied significantly. Participants with cerebrovascular or peripheral arterial disease were prescribed less cardiovascular medication than those with coronary artery disease (CAD) (mean number of drugs 3.5 vs. 4.5, P < 0.0001) and (3.6 vs. 4.5, P < 0.0001), while those with risk factor alone had the same medication use as those with CAD (mean number 4.5). Medication use was lower in Western Australia in comparison to eastern States. Participants with existing cerebrovascular disease and peripheral vascular disease receive less preventive therapy than those with CAD or even risk factors alone. This observation is consistent across all mainland states. Given the evidence of the effectiveness and cost-effectiveness of treating all types of vascular diseases, the present study suggests that there is scope to improve the treatment of these high-risk participants in Australia.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02F</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Médicament</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Drug</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Medicamento</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Traitement</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Treatment</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Coût moyen</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Average cost</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Coste medio</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Economie santé</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Health economy</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Economía salud</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Australie</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Australia</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Australia</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Médecine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Medicine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Medicina</s0>
<s5>07</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Océanie</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Oceania</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Oceania</s0>
<s2>NG</s2>
</fC07>
<fN21><s1>264</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003401 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 003401 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:09-0362027
   |texte=   Drug Treatment and Cost of Cardiovascular Disease in Australia
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Drug Treatment and Cost of Cardiovascular Disease in Australia

Drug Treatment and Cost of Cardiovascular Disease in Australia

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri